India’s Global Calcium and China’s Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical are the latest to be hit with warning letters from U.S. regulators.
The actions could postpone NIH-funded clinical trials and create cash flow issues for biotech companies, according to data and analytics firm GlobalData.
The vaccine maker’s fourth quarter results included a loss of about $238 million on a non-cash charge related to the termination of a contract manufacturing agreement.
